CaseyDE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry1996; 57 (suppl 11):40–5.
2.
Physicians' desk reference. Montvale, NJ: Medical Economics, 2001.
3.
NeedlmanRD. Growth and development. In: BehrmanREKliegmanRMJensonHB, eds. Nelson textbook of pediatrics. 16th ed.Philadelphia: WB Saunders, 2000: 23–65.
4.
ChaySHHermanJL. Disposition of the novel anti-schizophrenic drug [14C] olanzapine in male Fischer 344 and female CD rats following single oral dose administration. Arzneimittelforschung1998; 48: 446–54.
5.
SchenkerSYangYMattiuzETatumDLeeM. Olanzapine transfer by human placenta. Clin Exp Pharmacol Physiol1999; 26: 691–7.
6.
TizzanoJGriffeyKJohnsonASchwierPSauterSByrdR. Implementing the ICH guidelines: Developmental toxicology of olanzapine given orally to CD rats. Neurotoxicol Teratol1994; 16: 317–8.
7.
AltshulerLLCohenLSzubaMPBurtVKGitlinMMintzJ. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry1996; 153: 592–606.
8.
KirchheinerJBerghoferABolk-WeischedelD. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry2000; 33: 78–80.
9.
LittrellKHJohnsonCGPeabodyCDHilligossN. Antipsychotics during pregnancy (letter). Am J Psychiatry2000; 157: 1342.
10.
GoldsteinDJCorbinLAFungMC. Olanzapine-exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol2000; 20: 399–403.
